Navigation Links
Questcor Pharmaceuticals to Participate in Morgan Stanley Global Healthcare Conference
Date:9/5/2013

ANAHEIM, Calif., Sept. 5, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management will host investor meetings and will be a participant in a fireside chat session at the Morgan Stanley Global Healthcare Conference in New York City on September 10, 2013 at 4:40 PM ET/1:40 PM PT. The Conference does not accommodate formal presentations or the use of slides so there will not be a webcast presentation.

About Questcor

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Questcor also provides specialty contract manufacturing services to the global pharmaceutical industry through its wholly-owned subsidiary BioVectra Inc. Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from the following approved indications: the treatment of proteinuria in the nephrotic syndrome of the idiopathic type, or NS, the treatment of acute exacerbations of multiple sclerosis, or MS, in adults, the treatment of infantile spasms, or IS, in infants and children under two years of age, and the treatment of certain rheumatology related conditions. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor has announced its intent to initiate a pilot commercialization effort for Acthar for the treatment of respiratory manifestations of symptomatic sarcoidosis.  The FDA approved package insert for Acthar includes "symptomatic sarcoidosis" under the heading "Respiratory Diseases".  Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. Questcor also has agreed to acquire certain international rights for Synacthen® (tetracosactide) and Synacthen Depot®, and has licensed the right to develop and seek FDA approval for these products in the United States.  For more information about Questcor, please visit www.questcor.com.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor Pharmaceuticals to Present at JMP Securities Healthcare Conference
2. Questcor to Report Second Quarter Results on July 24, 2012
3. Questcor Reports Second Quarter Financial Results
4. Questcor Pharmaceuticals to Present at Investor Conferences in September
5. Questcor and The Myositis Association Team Up To Support Research and Educational Initiatives in Polymyositis and Dermatomyositis
6. Questcor Comments on Insurance Policy Bulletin
7. Questcor to Conduct Conference Call to Discuss Reimbursement Process
8. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
9. Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012
10. Questcor Pharmaceuticals Appoints Michael Aldridge to the Position of Senior Vice President, Corporate Strategic Development
11. Questcor to Report Fourth Quarter and Full Year 2012 Financial Results on February 26, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2020)... ... 02, 2020 , ... AllenComm, the leader in transformative learning experiences , ... visually compelling compliance training , onboarding , brand training , and ... industry expectations as a digital transformation partner for learning and development experts. , ...
(Date:7/1/2020)... ... , ... Dexur’s analysis of medicare claims of hospitals within a 25-mile radius ... General Health Center , and Lutheran Hospital had the best value ... analysis tracks a patient’s episode of care from the date of admission for 90 ...
(Date:6/28/2020)... , ... June 26, 2020 , ... ... Health' campaign. The campaign brings together patients, healthcare providers, advocates, and scientists to ... prevention, and treatment for these devastating respiratory conditions. , More than ...
Breaking Medicine Technology:
(Date:7/10/2020)... Calif. (PRWEB) , ... July 10, 2020 , ... Traliant, ... today announced a new training course for managers on the Family and Medical Leave ... FMLA with paid sick and family leave provisions related to COVID-19. , ...
(Date:7/7/2020)... (PRWEB) , ... July 07, 2020 , ... Dr. ... clients a new way to improve their scalp health. It is now possible to ... adding this treatment process to his practice, Dr. DeJoseph is able to provide clients ...
(Date:7/4/2020)... SAN FRANCISCO, Calif. (PRWEB) , ... July 03, ... ... promising scientific breakthroughs are prominently featured in Biocompare’s latest content hub— Future Lab: ... designed to showcase the latest advancements, trends, news, and products within specific scientific ...
(Date:7/2/2020)... ... July 02, 2020 , ... ... the treatment of autoimmune diseases. Its lead indication is vitiligo. Vitiligo patients ... this time. , While vitiligo is equally prevalent in all ethnic ...
(Date:7/2/2020)... ... July 02, 2020 , ... Allegheny Health Network (AHN) today announced ... Information Officer (CMIO), effective immediately. Dr. Lee succeeds Robert White, MD, who announced ... the end of the year to help support a seamless transition. , Dr. Lee ...
Breaking Medicine News(10 mins):